Associations between neutrophil percentage-to-albumin ratio with all-cause and cause-specific mortality among US cancer survivors: evidence from NHANES 2005-2018

美国癌症幸存者中性粒细胞百分比与白蛋白比值与全因死亡率和特定原因死亡率之间的关联:来自 NHANES 2005-2018 年的证据

阅读:1

Abstract

BACKGROUND: The neutrophil percentage-to-albumin ratio (NPAR) had been suggested as a potential prognostic biomarker in various health outcomes. However, its association with mortality in cancer survivors remains unclear. METHODS: A total of 3,022 cancer survivors from the National Health and Nutrition Examination Survey (NHANES) 2005-2018 were linked to mortality outcomes from the National Death Index (NDI). Weighted Cox proportional hazards models was conducted to investigate the association between NPAR and all-cause, cancer and cardiovascular disease (CVD) mortality and the hazard ratio (HR) with 95% confidence interval (CI) were calculated. Restricted cubic spline (RCS) was used to clarify the non-linear association. Additionally, analyses for stratification and sensitivity were performed. RESULTS: During a median follow-up of 75 months, 790 all-cause deaths occurred, including 244 from cancer and 209 from CVD. After adjustment for covariates, higher NPAR was independently associated with increased risk of all-cause mortality (HR = 1.09, 95% CI = 1.06-1.13), cancer mortality (HR = 1.05, 95% CI = 0.99-1.12), and CVD mortality (HR = 1.13, 95% CI = 1.06-1.21). The RCS revealed a U-shaped relationship for all-cause and cancer mortality, with thresholds of 12.76 and 13.60, respectively. Below the threshold, higher NPAR was associated with a reduced risk of mortality (HR = 0.90, 95% CI = 0.82-0.99; HR = 0.87, 95% CI = 0.76-0.99), whereas above the threshold, the risk of mortality increased significantly (HR = 1.14, 95% CI = 1.09-1.18; HR = 1.15, 95% CI = 1.07-1.24). Subgroup and sensitivity analyses confirmed these findings. CONCLUSION: The U-shaped association with all-cause and cancer mortality, along with the linear association with CVD mortality, underscores the potential of NPAR as a valuable prognostic marker in cancer survivors.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。